Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention

Journal of the American College of Cardiology

Volumn 45, Issue 3, 2005, Pages 369-376

  Cowper, Patricia A ^a,b   Udayakumar, Krishna ^b   Sketch Jr , Michael H ^b   Peterson, Eric D ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HOSPITAL COST; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 13244277713     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.10.041     Document Type: Article

References (25)

1. American Heart Association Heart Disease and Stroke Statistics, 2004 Update 2003 American Heart Association Dallas, TX
2. D.L. Bhatt, M.E. Bertrand, P.B. Berger Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting J Am Coll Cardiol 39 2002 9 14
3. A. Schomig, F.J. Neumann, A. Kastrati A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents N Engl J Med 334 1996 1084 1089
4. P. Eriksson Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the 'Emperor's New Clothes' revisited Eur Heart J 25 2004 720 722
5. E. Braunwald, E.M. Antman, J.W. Beasley The ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article J Am Coll Cardiol 40 2002 1366 1374
6. S.R. Steinhubl, P.B. Berger, J.T. Mann III Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (erratum in JAMA 2003;289:987) JAMA 288 2002 2411 2420
7. S.R. Mehta, S. Yusuf, R.J.G. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
8. B.R. Luce, W.G. Manning, J.E. Siegel, J. Lipscomb Estimating costs in cost-effectiveness analysis M.R. Gold J.E. Siegel L.B. Russell M.C. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York, NY 176 213
9. J.M. Eisenberg Clinical economics: a guide to the economic analysis of clinical practices JAMA 262 1989 2879 2886
10. Ingenix Inc. DRG Expert: A Comprehensive Guidebook to the DRG Classification System 19th edition 2002 St. Anthony Publishing/Medicode Reston, VA
11. Health Care Financing Review: Medicare and Medicaid Statistical Supplement, 2001 2003 U.S. Department of Health and Human Services Baltimore, MD
12. A.M. Lincoff, D.B. Mark, J.E. Tcheng Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade (EPILOG) randomized trial Circulation 102 2000 2923 2929
13. CIGNA HealthCare Medicare Administration. www.cignamedicare.com/partb/ fsch/archive.html. Accessed July 20, 2004.
14. Thompson Medical Economics. Red Book 2000 Thompson Medical Economics Company, Inc. Montvale, NJ
15. U.S. Department of Labor, Bureau of Labor Statistics. Producer Price Indexes. www.bls.gov/ppi/home.htm. Accessed July 20, 2004.
16. A. Peeters, A.A. Mamun, F. Willekens, L. Bonneux A cardiovascular life history: a life course analysis of the original Framingham Heart Study cohort Eur Heart J 23 2002 458 466
17. D.B. Mark, R.A. Harrington, A.M. Lincoff Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes Circulation 101 2000 366 371
18. J. Lipscomb, M.C. Weinstein, G.W. Torrance Time preferences M.R. Gold J.E. Siegel L.B. Russell M.C. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York, NY 214 235
19. J.D. Graham, P.S. Corso, J.M. Morris, M. Segui-Gomez, M.C. Weinstein Evaluating the cost-effectiveness of clinical and public health measures Ann Rev Public Health 19 1998 125 152
20. D.M. Huse, M.W. Russell, J.D. Miller Cost-effectiveness of statins Am J Cardiol 82 1998 1357 1363
21. J.S. Schwartz Comparative economic data regarding lipid-lowering drugs Am Heart J 137 1999 S97 104
22. E.D. Peterson, P.A. Cowper, E.R. DeLong, J.P. Zidar, R.S. Stack, D.B. Mark Acute and long-term cost implications of coronary stenting J Am Coll Cardiol 33 1999 1610 1618
23. H.M. Krumholtz, C.P. Gross, E.D. Peterson Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study Am Heart J 146 2003 839 847
24. D.F. Kong, V. Hasselblad, R.A. Harrington Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions Am J Cardiol 92 2003 651 655
25. P. Lindgren, B. Jonsson Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial J Intern Med 255 2004 562 570